Analysts anticipate FibroGen to report an earnings per share (EPS) of $-0.30. Investors in FibroGen are eagerly awaiting the ...

Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for ...

FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong ...

FibroGen (FGEN) announced that the China State Administration for Market Regulation approved the sale of FibroGen International to AstraZeneca ...

FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical ...

FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its ...

FibroGen appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

FibroGen said it is in the process of evaluating the overall data to determine next steps for the program. FibroGen shares are down 92% in the year to date, while the S&P 500 SPX has gained 17%.

FibroGen plans to file up to two INDs: FG-3165 (1Q 2024) and FG-3163 (4Q 2023). Additionally, the company expects to initiate a Phase 2 trial of FG-3246, targeting metastatic castration-resistant ...

FibroGen was evaluating the DMD therapy, pamrevlumab, in a late-stage trial in patients with non-ambulatory forms of the disorder, versus a placebo.

Last month, we discussed that FibroGen (NASDAQ: FGEN) stock price could rebound over a one-month period after falling 6% in a week, based on the Trefis Machine Learning Engine. However, FGEN stock ...

The stock price of FibroGen (NASDAQ: FGEN), a biopharmaceutical company focused on therapeutics in immunology and oncology, reached its 52-week high of $56 in February this year before a larger ...